20-F: Fresenius Medical Care Reports Strong 2025 Earnings, Accelerates Share Buyback

Fresenius Medical Care AG announced a significant increase in net income and operating income for 2025, alongside an accelerated share buyback program and strategic portfolio optimization.

Summary

• Revenue increased by 2% (5% at constant currency) to €19.63 billion in 2025.
• Operating income rose by 31% (36% at constant currency) to €1.83 billion.
• Net income attributable to shareholders of FME AG surged by 82% (88% at constant currency) to €978.4 million.
• Basic earnings per share increased by 83% to €3.36.
• Return on Invested Capital (ROIC) improved to 5.0% in 2025 from 3.5% in 2024.
• Net leverage ratio improved to 2.5x at December 31, 2025, from 2.9x at December 31, 2024.
• The €1 billion share buyback program was accelerated, with the first tranche of €586 million completed by December 29, 2025, ahead of schedule.
• The company introduced its new FME Reignite strategy, focusing on strengthening core operations, driving profitable growth and innovation, and developing culture.
• Divestitures under the Legacy Portfolio Optimization program included clinic operations in Brazil, Malaysia, Kazakhstan, and select assets of Spectra Laboratories.
• The Value-Based Care segment, a new operating segment as of June 1, 2025, recorded operating income in 2025 compared to a loss in 2024, driven by favorable savings rates and contract expansion.
• The company purchased its production sites in Schweinfurt and St. Wendel, Germany, from Fresenius SE for €181 million.
• HVHDF (High-Volume Hemodiafiltration) was introduced into clinical practice in the U.S. in 2025, with a broader commercial launch planned for 2026.
• Total headcount decreased by 2% to 109,698 employees, largely due to divestitures.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong financial performance, marked by significant increases in profitability metrics and an improved balance sheet, despite ongoing macroeconomic and regulatory headwinds. The strategic initiatives and accelerated share buyback signal confidence in future growth, though the extensive list of risks warrants careful monitoring.

Positives

• Net income attributable to shareholders of FME AG increased by 82% (88% at constant currency) to €978.4 million.
• Operating income increased by 31% (36% at constant currency) to €1.83 billion.
• Basic earnings per share increased by 83% to €3.36.
• Return on Invested Capital (ROIC) improved significantly to 5.0% from 3.5%.
• Net leverage ratio improved to 2.5x from 2.9x, indicating stronger financial health.
• The €1 billion share buyback program was accelerated, with the first tranche completed ahead of schedule.
• Successful introduction of High-Volume Hemodiafiltration (HVHDF) in the U.S. clinical practice, with plans for broader commercial launch.
• Value-Based Care segment achieved operating income in 2025, a turnaround from an operating loss in 2024.
• Successful divestiture of non-core assets under the Legacy Portfolio Optimization program.
• Strong organic growth across all segments contributed to revenue increase.
• Positive pricing momentum and volume increases in Care Enablement products.
• Improved cash collections and favorable phasing of income tax payments contributed to increased net cash from operating activities.

Negatives

• Revenue growth was modest at 2% as reported, with a negative impact from foreign currency translation and divestitures.
• Higher personnel expenses, including elevated medical benefit costs, partially offset operating income gains.
• Inflationary cost increases continued to impact operating costs.
• Negative impact from Humacyte Remeasurements on other operating income and expense.
• Unfavorable impact from foreign currency transaction effects.
• Decrease in dialysis treatments and patient numbers in Care Delivery due to closed or sold operations.
• The early termination of the ETC model by CMS as of December 31, 2025, will discontinue PPAs and return dialysis facilities to standard Medicare reimbursement rates in 2026.
• The expiration of ACA enhanced tax credits on December 31, 2025, is expected to reduce private ACA exchange insurance patients, potentially shifting them to lower-paying Medicare and Medicaid.
• The One Big Beautiful Bill Act (OBBBA) includes provisions that limit coverage in Medicaid, Medicare, and ACA exchanges, with approximately $1 trillion in Medicaid funding cuts through 2034.
• Volume-based procurement and other regulatory policies in China negatively impacted pricing in Care Enablement.

Risks

• Changes in governmental and private payor reimbursement, including potential significant changes to the ACA and the impact of the Loper Bright decision on regulatory interpretations.
• Inability to accurately interpret and comply with complex current and future government regulations, including sanctions, export control, environmental, social, and governance topics, and antitrust laws.
• Influence of private payors to manage costs by limiting healthcare benefits, narrowing networks, reducing provider reimbursement, and restricting patient funding options, exacerbated by the Marietta ruling.
• Impact of worldwide pandemics, including increased opposition to vaccinations, changes in government policies, and global virus impacts on patients, caregivers, employees, and supply chains.
• Inability to attract and retain skilled employees, leading to higher personnel costs, decreased productivity, and partial suspension of operations.
• Increase in raw material, energy, labor, and other costs, including impacts from geopolitical conflicts (e.g., Ukraine War) and inflation.
• Outcome of litigation, government, and internal investigations, including whistleblower suits.
• Launch of new technology, introduction of generic or new pharmaceuticals and medical devices, advances in medical therapies (e.g., GLP-1 receptor agonists, SGLT2 inhibitors), and new market entrants.
• Product liability risks and the risk of recalls of products by regulators.
• Ability to successfully launch the 5008X dialysis machine and related disposables and introduce HVHDF in the U.S.
• Impact of currency and interest rate fluctuations, including heightened risk from geopolitical conflicts and macroeconomic inflationary environment.
• Volatility in the valuation of financial instruments connected to energy prices or energy production volumes (e.g., virtual power purchase agreements).
• Potential impairment of goodwill, investments, or other assets due to decreases in recoverable amount, sovereign rating downgrades, economic downturns, or changes in government regulations.
• Ability to protect information technology systems and protected health information against cyber-attacks and other unauthorized access.
• Changes in costs of purchasing and utilization patterns for pharmaceuticals and other healthcare products, inability to procure raw materials, or supply chain disruptions.
• Economic uncertainty from tariffs, trade barriers, sanctions, and geopolitical conflicts.
• Collectability of receivables, dependent on billing practices, financial stability of payors, and third-party services.
• Ability to secure contracts and achieve cost savings and desired clinical outcomes in value-based care operations.
• Greater size, market power, experience, and product offerings of certain competitors.
• Use of accounting estimates, judgments, and accounting pronouncement interpretations.
• Ability to continue to achieve projected cost savings and implement the FME Reignite strategy, including the FME25+ Program.
• Ability to improve financial performance through divestiture of non-core and dilutive assets.
• Ability to achieve projected price increases for products and services.
• Risks from global operations, including economic and political instability, difficulties in enforcing receivables, local regulations restricting ownership, and trade restrictions.
• Exposure to product liability, patent infringement, and other claims.
• Violations of the U.S. Foreign Corrupt Practices Act and similar worldwide anti-corruption laws.
• If investments or value and risk-based care programs are found to have violated the law.
• If physicians and other referral sources cease referring patients or purchasing products.
• Failure to estimate, price for, and manage medical costs effectively in value and risk-based care programs.
• Significant risks associated with estimating healthcare service revenues.
• Diverging views of fiscal authorities or changes in tax legislation.
• Dependency on payment behavior and decision-making of business partners affecting collectability of accounts receivable.
• Indebtedness may prevent fulfilling debt-service obligations or implementing business strategy.
• Fresenius SE's significant influence over the company's management.
• Inability to meet applicable legal requirements and/or market expectations with respect to sustainability, including fines and financial burdens from ESG regulations.
• Risks associated with unpredictable events, such as public health crises and epidemics/pandemics.

Future Outlook

The company aims to achieve industry-leading profitability with an operating income margin in the mid-teens percentage range by 2030. It expects to generate operating cash flow of at least €2.5 billion annually through 2030. Capital expenditures are anticipated to be around €0.8 billion to €1.0 billion in 2026, driven by growth opportunities including the large-scale rollout of the HVHDF-capable 5008X CAREsystem, targeting replacement of 20% of machines in 2026 and 100% by 2030. The share buyback program is expected to be completed significantly earlier than originally planned, in less than a year, with the second tranche repurchase planned from January 12 to May 8, 2026. The company will remain disciplined with regard to acquisition and investment spending, focusing on organic growth.

Management Comments

• "The FME Reignite strategy sets the ambition to deliver both industry-leading outcomes and margins with above-market growth, positioning the Company to lead kidney care through exceptional patient care and innovation."
• "Leveraging the power of vertical integration... creates a basis to deliver industry-leading treatment, outcomes, and economics across our three operating segments... as well as improve patient outcomes, unlock efficiencies, and reinforce synergies across kidney care."
• "HVHDF... represents a significant opportunity to enhance patient outcomes and expand our presence in the U.S. dialysis market."
• "Our current research is now focused on developing real-world methods to enhance the removal of CMPF, aiming to mitigate its impact on anemia and improve patient outcomes."
• "The introduction of the 5008X CAREsystem together with HVHDF in the U.S. will allow us to further reduce our environmental impact by removing the need for most saline bags for dialysis while enabling a more efficient use of water, energy, and dialysis concentrates in dialysis clinics."
• "The Company endeavors to assist FME Group’s board members, directors, officers and employees with complying with the Insider Dealing Rules and avoiding Insider Dealing or any other misuse of Inside Information."

Industry Context

StockSavvy.ai notes that Fresenius Medical Care operates in a global kidney care market experiencing consistent growth (4-5% annually, projected to reach 7 million patients by 2035) driven by aging populations and increasing prevalence of chronic diseases like diabetes and hypertension. The company's FME Reignite strategy, with its focus on vertical integration and value-based care, aligns with broader industry trends towards integrated care models and outcomes-based reimbursement. The rollout of HVHDF in the U.S. positions the company at the forefront of advanced dialysis technology, potentially setting a new standard of care, while also addressing sustainability concerns. However, the industry faces ongoing pressures from government reimbursement changes, consolidation among payors, and the emergence of new pharmaceutical therapies (e.g., GLP-1, SGLT2 inhibitors) that could impact patient populations and treatment pathways, requiring continuous adaptation and innovation.

Comparison to Industry Standards

• Fresenius Medical Care is the world's leading provider of products and services for individuals with kidney diseases based on publicly reported revenue.
• The company manages the world's largest network of dialysis centers, treating about 7% of all dialysis patients globally.
• Fresenius Medical Care is the global market leader for dialysis products, holding around 35% market share in 2025.
• In hemodialysis products alone, Fresenius Medical Care is the leading provider, holding over 40% of the global market share.
• The company is the market leader in HD machines, producing around 50% of the estimated 110,000 machines installed in 2025.
• Fresenius Medical Care holds the largest share of the Home Hemodialysis (HHD) market, with more than 75% of all HHD patients utilizing its machines.
• In the U.S. government's Kidney Care Choices (KCC) program, the majority of the company's aligned nephrology practices (KCEs) are considered high performers, contributing 80% of the entire KCC program's gross savings in 2022 (based on latest publicly published data).
• The company's Value-Based Care segment achieves optimal start rates over twice as high as the U.S. national average.
• Compared to competitors like DaVita, Inc., Diaverum AB, B. Braun SE, U.S. Renal Care, Inc., and Nephrocare Health Services Limited (NephroPlus) in services, and Akebia Therapeutics, Inc., Nipro Corporation, Outset Medical, Inc., and Toray Medical Co., Ltd. in products, Fresenius Medical Care maintains a leading position across multiple segments.

Management Changes

Corporate Governance

Legal Proceedings

• Hessian prosecutor opened independent disgorgement proceedings against a German subsidiary in September 2023 related to legacy conduct in West Africa with a potential nexus to Germany.
• United States ex rel. Pepe and Sherman v. Fresenius Vascular Care, Inc. et al.: Consolidated complaint-in-intervention filed by New York, New Jersey, and Georgia in October 2023, alleging billing for medically unnecessary surgery. FMCH's motion to dismiss relators' complaint granted in October 2024.
• Subpoena from the Attorney General for the District of Columbia received on January 3, 2023, related to activities of the American Kidney Foundation (AKF) and anti-trust concerns.
• London Court of International Arbitration: Arbitral tribunal dismissed former distributor's claims in Iraq and granted the Company's counterclaims on October 28, 2025.
• Civil Investigative Demands (CIDs) from the U.S. Federal Trade Commission (FTC) received on April 5, 2024, investigating anti-competitive conduct in acquiring medical director services or providing dialysis services.
• Florida Antitrust Act CID received on May 2, 2025, from the Attorney General of Florida, investigating possible anti-competitive conduct similar to the FTC investigation.
• CID received on December 1, 2025, from the Attorney General for the State of Washington, investigating possible anti-competitive conduct similar to the FTC investigation.
• CID received on March 24, 2025, from the U.S. DOJ concerning an investigation into Azura Vascular Care for allegedly billing for medically unnecessary intravascular ultrasound procedures and upcoding.
• United Food and Commercial Workers Local 1776 and Participating Employers Health and Welfare Fund, et al. v. Fresenius Medical Care AG and Fresenius Medical Care Holdings, Inc.: Purported class action lawsuit filed on May 9, 2025, alleging violations of U.S. antitrust laws including price fixing and territory allocation.
• Antimonopoly Committee of Ukraine (AMCU) ruled on December 18, 2025, that a Ukrainian subsidiary engaged in anti-competitive conduct and imposed a fine of around €543 thousand and a three-year ban from public tenders.
• FDA warning letter issued on December 4, 2023, citing deficiencies in cGMP requirements related to silicone tubing in dialysis machines; remediation efforts ongoing.
• Two putative class action lawsuits pending in connection with a security incident at Cardiovascular Consultants, Ltd. (CCL) and Fresenius Vascular Care, Inc. (Azura) in September 2023. The Azura lawsuit was settled on a class-wide basis, and the CCL lawsuit reached an agreement in principle to settle.

Related Party Transactions

• Fresenius SE & Co. KGaA (Fresenius SE) remains the largest shareholder, owning 27.8% of issued shares at December 31, 2025.
• Long Form of Amendment to the Trademark License Agreement dated December 22, 2025, was signed between Fresenius SE & Co. KGaA and Fresenius Medical Care Deutschland GmbH, clarifying the scope of license for "Fresenius" marks and introducing termination rights and reporting obligations.
• Fresenius Medical Care Deutschland GmbH purchased production sites in Schweinfurt and St. Wendel, Germany, from Fresenius SE Companies for €181 million (purchase price of €171 million to Fresenius SE Companies) effective December 31, 2025.
• The company continues to have service agreements with Fresenius SE Companies for administrative, facility management, employee benefit administration, IT, and treasury services.
• The company provides administrative services to Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP), an equity method investee (45% owned).
• The company has exclusive supply and distribution agreements with VFMCRP for certain pharmaceuticals, with purchase obligations of approximately €226.7 million for 2026.
• Outstanding accounts payable related to a cash pooling program with certain equity-method investees amounted to €12.96 million at December 31, 2025.
• The company's unfunded pension plan in Germany includes benefit obligations of former board members of Management AG (former general partner) and active board members appointed before January 1, 2019, totaling €55.43 million at December 31, 2025.
• The defined contribution pension plan funded by insurance contracts for active board members appointed after January 1, 2019, was settled in 2025 through an early payment.

Stakeholder Impact

• Shareholders: Positive impact from increased profitability, improved ROIC, reduced net leverage, and accelerated share buyback program. Potential for higher dividends (proposed €1.49/share). Risks include potential dilution from future capital raises, impact of regulatory changes on share price, and influence of major shareholder Fresenius SE.
• Patients: Positive impact from the FME Reignite strategy focusing on patient outcomes, innovation (HVHDF rollout), and personalized medicine. Continued commitment to high-quality dialysis care and expansion of home dialysis options. Risks include potential disruptions from regulatory changes affecting access to care or reimbursement, and impacts from global health crises.
• Employees: Potential for increased employee satisfaction (a sustainability target for STI). Risks include headcount reduction due to divestitures and portfolio optimization, labor shortages, high turnover rates, and increased personnel costs. Union organizing activity in California could impact labor relations.
• Customers (Healthcare Providers): Benefit from advanced products like the 5008X CAREsystem and support for value-based care models. Risks include pricing pressures from volume-based procurement (e.g., China) and changes in reimbursement affecting their own profitability.
• Suppliers: Potential for stable partnerships through framework contracts and continuous supply chain monitoring. Risks include increased scrutiny on sustainability practices and potential for price increases due to inflation and geopolitical conflicts.
• Creditors: Improved net leverage ratio and strong cash flow generation enhance creditworthiness. The company's financing strategy aims for financial flexibility and managing financial risks. Risks include overall indebtedness and potential for rating downgrades if financial performance deteriorates.
• Regulatory Authorities: Increased scrutiny on compliance, anti-competitive practices, and data privacy. The company is actively engaged in various investigations and remediation efforts.

Next Steps

• Broader commercial launch of HVHDF-capable 5008X CAREsystem in the U.S. in 2026 and beyond.
• Target to replace around 20% of machines in 2026 with the 5008X CAREsystem, with the ultimate goal of replacing 100% by 2030.
• Accelerated capital expenditures in new production facilities and R&D activities for a more globalized product portfolio.
• Repurchase of the second tranche of the share buyback program (€414 million) from January 12 to May 8, 2026.
• Supervisory Board intends to propose a dividend of €1.49 per share for 2025 at the AGM on May 21, 2026.
• Transitional process for the divestment of select Spectra Laboratories assets will continue into 2026.
• Planned finalization of certification process for one remaining product category under EU MDR in 2026.
• Submission of registration for citrate solution in the U.S. in December 2025, with market launch expected in 2026.
• Further key launches for Korsuva/Kapruvia expected in the next 12 months.
• Rollout of kinexus PD remote therapy management to additional countries in Europe and Asia started in 2025.
• Advanced monitor and Secure Connectivity Board (SCB) for multiFiltratePRO platform scheduled for release in 2026.
• Next quality assessment for Global Internal Audit planned for 2026.
• Union organizing activity in California (U.S.) expected to continue in 2026.
• Directors and officers will be required to report ownership and transactions in equity securities pursuant to Section 16 of the Securities and Exchange Act of 1934 commencing March 18, 2026.

Key Dates

Recommendation

The company demonstrated strong financial performance in 2025 with significant increases in net income, operating income, and EPS, coupled with an improved ROIC and net leverage ratio. The accelerated share buyback program signals management's confidence and commitment to shareholder returns. Strategic initiatives like FME Reignite and the HVHDF rollout position the company for future growth and innovation in a growing market. While regulatory and legal risks are notable, the current financial trajectory and strategic focus suggest a positive outlook for long-term investors.

Keywords

Dialysis, Kidney Care, Renal Disease, Healthcare Services, Medical Devices, Pharmaceuticals, SEC Filing, Financial Results, Earnings, Revenue, Operating Income, Net Income, EPS, Share Buyback, FME Reignite, Value-Based Care, High-Volume Hemodiafiltration, HVHDF, Regulatory Risk, Compliance, Cybersecurity, ESG, Mergers and Acquisitions, Divestitures, Fresenius Medical Care